Abstract
Plasma cell leukemia is a rare form of multiple myeloma (MM). In contrast to de novo primary plasma cell leukemia (pPCL), which is very uncommon presentation of MM, there is increasing frequency of transformation to secondary plasma cell leukemia (sPCL) with increasing survival of patients (MM). The molecular basis of sPCL remains poorly understood sPCL is particularly aggressive and is associated with an extremely poor prognosis, constituting a major unmet medical need. High-quality data in sPCL regarding presentation, treatment and outcomes is limited. Herein we review the current state of knowledge on sPCL diagnostics, molecular biology, clinical characteristics, prognosis and reported treatment outcomes and the emergence of the new therapeutic strategies.
| Original language | English |
|---|---|
| Pages (from-to) | 188-193 |
| Number of pages | 6 |
| Journal | Clinical Lymphoma, Myeloma and Leukemia |
| Volume | 23 |
| Issue number | 3 |
| DOIs | |
| State | Published - Mar 2023 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Diagnosis
- Plasma cell dyscrasia
- Prognosis
- Secondary plasma cell leukemia
- Therapy
Fingerprint
Dive into the research topics of 'The Current State of Knowledge About Evolution of Multiple Myeloma to Plasma Cell Leukemia'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver